313 related articles for article (PubMed ID: 29739347)
21. Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients.
Zhang S; Li L; Wang T; Bian L; Hu H; Xu C; Liu B; Liu Y; Cristofanilli M; Jiang Z
BMC Cancer; 2016 Jul; 16():526. PubMed ID: 27456503
[TBL] [Abstract][Full Text] [Related]
22. Clinical relevance of H-RAS, K-RAS, and N-RAS mRNA expression in primary breast cancer patients.
Banys-Paluchowski M; Milde-Langosch K; Fehm T; Witzel I; Oliveira-Ferrer L; Schmalfeldt B; Müller V
Breast Cancer Res Treat; 2020 Jan; 179(2):403-414. PubMed ID: 31646390
[TBL] [Abstract][Full Text] [Related]
23. The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer.
Wallwiener M; Hartkopf AD; Baccelli I; Riethdorf S; Schott S; Pantel K; Marmé F; Sohn C; Trumpp A; Rack B; Aktas B; Solomayer EF; Müller V; Janni W; Schneeweiss A; Fehm TN
Breast Cancer Res Treat; 2013 Jan; 137(2):503-10. PubMed ID: 23271327
[TBL] [Abstract][Full Text] [Related]
24. High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients.
Pierga JY; Hajage D; Bachelot T; Delaloge S; Brain E; Campone M; Diéras V; Rolland E; Mignot L; Mathiot C; Bidard FC
Ann Oncol; 2012 Mar; 23(3):618-624. PubMed ID: 21642515
[TBL] [Abstract][Full Text] [Related]
25. Insulin-like growth factor-1 receptor (IGF-1R) expression on circulating tumor cells (CTCs) and metastatic breast cancer outcome: results from the TransMYME trial.
Gennari A; Foca F; Zamarchi R; Rocca A; Amadori D; De Censi A; Bologna A; Cavanna L; Gianni L; Scaltriti L; Rossi E; Facchinetti A; Martini V; Bruzzi P; Nanni O
Breast Cancer Res Treat; 2020 May; 181(1):61-68. PubMed ID: 32200486
[TBL] [Abstract][Full Text] [Related]
26. [Value of serum human epithelial growth factor receptor 2 extracellular domain and circulating tumor cells in evaluating therapeutic response in advanced gastric cancer].
Li Y; Peng Z; Zhang X; Gong J; Shen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Nov; 20(11):1293-1299. PubMed ID: 29178102
[TBL] [Abstract][Full Text] [Related]
27. Clinical Significance of Circulating Tumor Cells in Hormone Receptor-positive Metastatic Breast Cancer Patients who Received Letrozole with or Without Bevacizumab.
Magbanua MJM; Savenkov O; Asmus EJ; Ballman KV; Scott JH; Park JW; Dickler M; Partridge A; Carey LA; Winer EP; Rugo HS
Clin Cancer Res; 2020 Sep; 26(18):4911-4920. PubMed ID: 32586939
[TBL] [Abstract][Full Text] [Related]
28. Interleukin 15 and Eotaxin correlate with the outcome of breast cancer patients vice versa independent of CTC status.
Vilsmaier T; Heidegger HH; Schröder L; Trapp E; Zehni AZ; Rack B; Janni W; Mahner S; Weissenbacher T; Jeschke U; Mumm JN;
Arch Gynecol Obstet; 2021 Jan; 303(1):217-230. PubMed ID: 32929618
[TBL] [Abstract][Full Text] [Related]
29. Detection of circulating tumor cells in breast cancer patients: prognostic predictive role.
Turker I; Uyeturk U; Sonmez OU; Oksuzoglu B; Helvaci K; Arslan UY; Budakoglu B; Alkis N; Aksoy S; Zengin N
Asian Pac J Cancer Prev; 2013; 14(3):1601-7. PubMed ID: 23679243
[TBL] [Abstract][Full Text] [Related]
30. Circulating tumor cells in HER2-positive metastatic breast cancer patients: a valuable prognostic and predictive biomarker.
Liu Y; Liu Q; Wang T; Bian L; Zhang S; Hu H; Li S; Hu Z; Wu S; Liu B; Jiang Z
BMC Cancer; 2013 Apr; 13():202. PubMed ID: 23617715
[TBL] [Abstract][Full Text] [Related]
31. Circulating tumor cells in newly diagnosed inflammatory breast cancer.
Mego M; Giordano A; De Giorgi U; Masuda H; Hsu L; Giuliano M; Fouad TM; Dawood S; Ueno NT; Valero V; Andreopoulou E; Alvarez RH; Woodward WA; Hortobagyi GN; Cristofanilli M; Reuben JM
Breast Cancer Res; 2015 Jan; 17(1):2. PubMed ID: 25572591
[TBL] [Abstract][Full Text] [Related]
32. Prognostic significance of circulating tumor cells (CTCs) in Egyptian non-metastatic colorectal cancer patients: A comparative study for four different techniques of detection (Flowcytometry, CellSearch, Quantitative Real-time PCR and Cytomorphology).
Bahnassy AA; Salem SE; Mohanad M; Abulezz NZ; Abdellateif MS; Hussein M; Zekri CAN; Zekri AN; Allahloubi NMA
Exp Mol Pathol; 2019 Feb; 106():90-101. PubMed ID: 30578762
[TBL] [Abstract][Full Text] [Related]
33. Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS-BRAF wild-type colorectal cancer receiving cetuximab or panitumumab.
Musella V; Pietrantonio F; Di Buduo E; Iacovelli R; Martinetti A; Sottotetti E; Bossi I; Maggi C; Di Bartolomeo M; de Braud F; Daidone MG; Cappelletti V
Int J Cancer; 2015 Sep; 137(6):1467-74. PubMed ID: 25704501
[TBL] [Abstract][Full Text] [Related]
34. Detection and prognostic relevance of circulating tumour cells (CTCs) in Asian breast cancers using a label-free microfluidic platform.
Yap YS; Leong MC; Chua YW; Loh KWJ; Lee GE; Lim EH; Dent R; Ng RCH; Lim JH; Singh G; Tan A; Guan G; Wu A; Lee YF; Bhagat AAS; Lim DW
PLoS One; 2019; 14(9):e0221305. PubMed ID: 31553731
[TBL] [Abstract][Full Text] [Related]
35. The Prognostic Value of HER2-Positive Circulating Tumor Cells in Breast Cancer Patients: A Systematic Review and Meta-Analysis.
Wang CH; Chang CJ; Yeh KY; Chang PH; Huang JS
Clin Breast Cancer; 2017 Aug; 17(5):341-349. PubMed ID: 28347604
[TBL] [Abstract][Full Text] [Related]
36. Impact of serum HER2, TIMP-1, and CAIX on outcome for HER2+ metastatic breast cancer patients: CCTG MA.31 (lapatinib vs. trastuzumab).
Ho D; Huang J; Chapman JW; Leitzel K; Ali SM; Shepherd L; Parulekar WR; Ellis CE; Crescnzo RJ; Zhu L; Virk S; Nomikos D; Aparicio S; Gelmon KA; Carney WP; Lipton A
Breast Cancer Res Treat; 2017 Aug; 164(3):571-580. PubMed ID: 28484925
[TBL] [Abstract][Full Text] [Related]
37. Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial.
Peña C; Lathia C; Shan M; Escudier B; Bukowski RM
Clin Cancer Res; 2010 Oct; 16(19):4853-63. PubMed ID: 20651059
[TBL] [Abstract][Full Text] [Related]
38. The prognostic value of the Tau protein serum level in metastatic breast cancer patients and its correlation with brain metastases.
Darlix A; Hirtz C; Thezenas S; Maceski A; Gabelle A; Lopez-Crapez E; De Forges H; Firmin N; Guiu S; Jacot W; Lehmann S
BMC Cancer; 2019 Jan; 19(1):110. PubMed ID: 30700265
[TBL] [Abstract][Full Text] [Related]
39. Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system?
Dawood S; Broglio K; Valero V; Reuben J; Handy B; Islam R; Jackson S; Hortobagyi GN; Fritsche H; Cristofanilli M
Cancer; 2008 Nov; 113(9):2422-30. PubMed ID: 18785255
[TBL] [Abstract][Full Text] [Related]
40. Impact of apoptotic circulating tumor cells (aCTC) in metastatic breast cancer.
Deutsch TM; Riethdorf S; Nees J; Hartkopf AD; Schönfisch B; Domschke C; Sprick MR; Schütz F; Brucker SY; Stefanovic S; Sohn C; Pantel K; Trumpp A; Schneeweiss A; Wallwiener M
Breast Cancer Res Treat; 2016 Nov; 160(2):277-290. PubMed ID: 27696083
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
